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Abstract
Background: Charging for tuberculosis (TB) treatment could reduce completion rates, particularly in the poor. We
identified and synthesised studies that measure costs of TB treatment, estimates of adherence and the potential
impact of charging on treatment completion in China.
Methods: Inclusion criteria were primary research studies, including surveys and studies using qualitative methods,
conducted in mainland China. We searched MEDLINE, PUBMED, EMBASE, Science Direct, HEED, CNKI to June 2010;
and web pages of relevant Chinese and international organisations. Cost estimates were extracted, transformed,
and expressed in absolute values and as a percentage of household income.
Results: Low income patients, defined at household or district level, pay a total of US$ 149 to 724 (RMB 1241 to
5228) for medical costs for a treatment course; as a percentage of annual household income, estimates range from
42% to 119%. One national survey showed 73% of TB patients at the time of the survey had interrupted or
suspended treatment, and estimates from 9 smaller more recent studies showed that the proportion of patients at
the time of the survey who had run out of drugs or were not taking them ranged from 3 to 25%. Synthesis of
surveys and qualitative research indicate that cost is the most cited reason for default.
Conclusions: Despite a policy of free drug treatment for TB in China, health services charge all income groups,
and costs are high. Adherence measured in cross sectional surveys is often low, and the cumulative failure to
adhere is likely to be much higher. These findings may be relevant to those concerned with the development and
spread of multi-drug resistant TB. New strategies need to take this into account and ensure patient adherence.
Background
In China, over 130,000 people die from tuberculosis
(TB) each year [1]. In 2004, 140,000 people were esti-
mated to have multidrug resistant tuberculosis (MDR
TB), about one third of the total worldwide [2]. It is
therefore particularly important that the health system
ensures the delivery of full treatment to those with the
disease.
China’s health system was decentralised in the 1980’s,
and the central government budget for health facilities
dropped to 10% of the total facilities’ revenue by the
early 1990s [3]. Health services were expected to gener-
ate revenue and manage surpluses [3]. Whilst
government controlled the price for basic health care,
they also established a margin for drug sales so facilities
could generate income and survive [4]. These initial
reforms meant TB patients were charged like everyone
else.
With increased TB incidence in the 1990’s thought to
be related to rural-urban migration [5], the government
responded by abolishing fees for TB diagnosis and treat-
ment. The TB control institutes are authorised to pro-
vide free TB drugs (6 months for new patients, 8
months if previously treated); and free X-ray examina-
tion at first visit, followed by a free sputum smear test.
Accompanying this, health workers in general health
facilities are obliged to refer TB suspects and patients to
local TB dispensary for diagnosis confirmation and
treatment. This national programme was organised cen-
trally and conducted at county (district/city) level;
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international agencies (e.g. World Bank) helped with
subsidies, loans and technical advice [6]. Performance
appeared remarkably high, with one report of a defaulter
rate of 1.6% in 55,213 new patients [7].
Despite the central government commitment to free
treatment, providers have found ways of generating rev-
enue from TB patients. There is clear evidence, for
example, that providers recommend treatment beyond
the period of free drugs; request repeated investigation
and follow up X-rays and blood tests; and prescribe
liver protection and ancillary drugs [1,8,9]. All of these
require payment, and are added on to the basic package
of free care provided in the TB programme. Does this
impact on adherence? Although the aggregate national
statistics indicate very high completion rates, the pro-
gramme is heavily target driven. It is possible that the
official figures are perhaps optimistic estimates; they
certainly hide regional and local variation where perfor-
mance may be poorer. When carefully conducted,
usually small, independent surveys are carried out that
record a problem with adherence, there is a difficulty in
interpretation: is this just a local problem, or more gen-
eralised? In such circumstances, a systematic review of
the small studies can help examine this. Given the ser-
ious potential public health impact of incomplete TB
treatment in 1,500,000 people under treatment each
year, we sought to summarise reliable evidence relevant
to these debates. We sought to answer three main
questions:
1) How much do TB patients pay for medical care?
2) What is the range of estimates for default?
3) Is there any evidence of a link between medical
care costs and adherence?
Methods
Criteria for considering studies for this review
This review included original research conducted in
mainland China, with explicit methods so it was clear
how the data had been collected. Criteria were specific
to each question: for patient costs and completion rates,
we sought surveys; for exploration of links between
costs and adherence, we sought relevant surveys and
qualitative data.
Inclusion criteria were carefully defined (Table 1) and
applied. Studies where there was no information on the
study design, study population and how data were col-
lected were excluded. This excludes routine health
information collected and collated by the health service.
We included research in Chinese or English published
between 1979 and June 2010.
Search strategy
We searched the following databases: MEDLINE,
PUBMED, EMBASE, Science Direct, HEED with the fol-
lowing search terms: Tuberculosis, adherence, treatment,
completion, cure; cost, financial burden; the poor, low
income, vulnerable group, migrants; Directly Observed
Treatment short-course (DOTs), initiatives, incentive,
health insurance, New Cooperative Medical Scheme,
China. The electronic search strategy for one database is
in Table 2. One Chinese database (CNKI) was searched
using terms “tuberculosis, treatment, cost, financial bur-
den, adherence”. This search was to identify studies in
Chinese that were not included in English databases
presented above. Google search and web pages of TB
control of Chinese Ministry of Health and other interna-
tional organisations (including the World Health Orga-
nization, World Bank) were screened in October 2010
and April 2011 for further relevant studies by searching
on “(tuberculosis or TB control) and “China”.
Data extraction and transformation
The first author identified studies based on examining
titles, and then abstracts. Full texts of relevant abstracts
were retrieved for further assessment. Data were
extracted using a standard form. Uncertainties were
resolved through discussion with co-authors and contact
with study authors. Data were extracted onto a single
form and the data extraction was checked by a second
author. The main outcome we sought was medical cost
Table 1 Inclusion criteria
Study question Inclusion criteria Data to be sought and extracted
1. Medical costs
to TB patient
Population-based surveys or facility-based surveys on TB
patients (including new and re-treatment patients)
Total and average cost; cost as a proportion of annual
household income
2. Adherence
rates
Population based surveys or cohort studies Completion or cure per patient followed up
3. Impact on
completion and
adherence
Surveys must be population based, with household or individual
cost estimates from interviews and completion rates based on
verified health service data, or on patient reported length of
treatment
A proportion of interrupted treatment because of financial
burden caused by TB treatment
Qualitative studies that a) use recognised methods (in-depth
interviews, focus group discussions, or observation); and b)
describe the methods used in analysis (thematic analysis,
content analysis, grounded theory)
Patient or provider views on cost and its influence on
treatment completion. Include evidence, in the form of
illustrative quotes or empirical data, for the statements
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of treatment; the variation in measuring cost of TB
treatment required some data conversion, that we did
using standard assumptions about length of treatment
for six months. Furthermore, we extracted or calculated
cost as a percentage of annual household income as an
indicator to assess TB patient’s financial burden by dif-
ferent study areas. We summarised data as brief narra-
tive for outcome measure.
Results
Description of studies
Figure 1 presents the review profile. The search
yielded 1143 studies for TB related diagnosis and
treatment, of which 247 studies (including 12 studies
having qualitative study design) potentially met the
inclusion criteria. On the second screening, we
excluded studies on the basis of the abstract. Sixty-
eight studies were retrieved for full-text evaluation
after screening the abstracts. Fifty-one studies were
excluded because they reported routine health service
surveillance data, or because they were duplicate
publications of a study already included, they provided
no relevant data, or no study methods or the defini-
tion of treatment completion was not clear (Figure 1).
Of the four national TB epidemic surveys between
1979 and 2000, only the 2000 study reported treat-
ment completion rate and was included.
In all, 17 studies (14 in English and 3 in Chinese)
met the inclusion criteria for questions 1-3. The study
design included surveys (14), both quantitative and
qualitative methods (2), and qualitative design only (1).
Studies were national (2); limited to 4 selected pro-
vinces in all regions (1); eastern (7); western (4); and
central (2); and unknown region due to authors con-
cerns about confidentiality (1). Most counties studied
were middle or low income; eleven studies were con-
cerned wholly with counties designated as World
Bank/TB Programme areas where TB drugs were sup-
plied for free (Table 3).
Medical costs
Nine studies provided estimates of total medical costs
per treatment (excluding transport and food) (Liu 2010,
Meng 2004, Jackson 2006, Zhang 2007, Xu 2010, Liu
2007, Xu 2006, Zhan 2004 and Huang 2009) (Table 4):
• RMB 1584 (US$ 220) per household for one treat-
ment was the average medical cost per treatment
among low income groups in 8 counties surveyed in
a study (n = 24), representing 93% of the total
annual household income in this group [8].
• RMB 2241 to 3070 (US$ 270 to 371) per house-
hold for one treatment was the range for the average
cost in each of 2 poor counties surveyed in a study
(n = 146), representing 57% to the maximum of
119% of average annual household income [10].
• RMB 1940 (US$ 242) was the total average out-of-
pocket payment for medical costs from diagnosis to
completion representing 39% of annual household
income in one carefully conducted study. The
authors interviewed the same patients (n = 144) on
two occasions in 4 counties where drugs were sup-
plied for free [11].
• RMB 1241 (US$ 149) of annual household medical
expense among low income households with a TB
patient (as a proxy indicator to estimate medical
cost for TB treatment) was the finding in the fourth
study (n = 80), representing 42% of annual house-
hold income in this group [12].
• RMB 4079 to 5228 (US$ 565 to 724) was the range
for annual household medical expense in two poor
counties (as a proxy indicator to reflect financial
situation of TB patients) in a fifth study (n = 156),
representing 65% to 84% of average annual house-
hold income [13].
Table 2 Electronic search strategy for one database
(Medline)
1 China [Mesh], ti, ab
2 Tuberculosis [Mesh], ti, ab
3 1 AND 2
4 Patient compliance [Mesh]
5 adherence OR DOT* OR (directly observed) ti, ab
6 (treatment completion) OR cost* OR finance* OR vulnerable OR
incentive* OR insurance OR fees OR monetary OR survey*) ti, ab
7 (low income*) OR (vulnerable group*) OR migrant* ti, ab
8 4 OR 5 OR 6 OR 7
9 3 AND 8
*The effects of strategies to mitigate treatment cost were not assessed in this review. 
247 potentially relevant 
studies on the basis of title
68 full-text assessment 
for eligibility
179 excluded mostly because data on other 
outcome measures:
• TB prevalence, detection, diagnosis and 
treament;
• TB suspect patients health seeking 
behaviour;
• TB knowledge and awareness among 
TB patients or public.
17 included
51 excluded:
23 used surveillance statistic data
10 duplicated report of study indicators 
in English and Chinese 
6  unclear study methods or definition 
of treatment completion 
5   no relevant data
3   quantiative data comparing between 
intervention and control groups*
2  specific cost on TB inpatient and 
surgical treatment
2   PhD thesis (relevant studies have 
been published separately)    
Figure 1 Identification of studiesD.
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Table 3 Description of included studies
Author
year
Data
collected
TB
patient
(n)
Province Sample
unit
Income
category,
status of
free
treatment
Methods Outcomes Data
collection
Questions
a
1 2 3
Liu
20108
2007 163 Chongqing
Sichuan
4
counties
in each
province
8 mixed
income,
All free
Patient survey Reported cost in previous
month on TB drugs and
tests
Postgraduate
students
●
Zhan
20049
2000-2001 257 Shandong
Jiangsu
Counties 3 middle,
1 free 2
not free
Patient survey Reported total medical cost
per treatment
Health staff ●
Meng
200410
2000 312 Shandong Counties 2 middle
income,
2 poor: All
free
Patient survey Reported total medical
annual cost per TB patient
Medical
students and
health staff
●
Liu
200714
2004 889 Fujian
Henan
Liaoning
Xinjiang
3
counties
in each
province
12 poor,
All free
Patient survey Reported direct household
cost per treatment
Health staff
from non-TB
system and
university
students
●
Huang
200916
2007 100 Hunan Counties 10
unknown,
All free
Patient survey Reported total medical cost
per treatment
Unknown ●
Xu
200615
2002-2003 465 Jiangsu Counties 2 middle
income,
1 free 1
not free
Longitudinal: 4
interviews per
patient b
1. Reported total medical
cost for treatment 2. Non-
adherence rate
TB specialist ● ●
Xu
201013
2008 501 Shandong Counties 6 mixed
income,
All free
Patient survey 1. Reported annual
household medical cost in
household with TB patient
2. Non-adherence rate
Independent
investigator
with help of
TB staff
● ●
Zhang
200712
2002 182 Whole of
rural China
N-A N-A Patient survey 1. Reported annual
household medical cost in
household with TB patient
2. Influence of charging on
treatment
Township
health
workers
● ●
Jackson
200611
2002-2005 160 Henan Counties 4 mixed
income,
All free
Longitudinal: 2
interviews per
patient c
1. Reported total medical
cost per completed
treatment 2. Non-
adherence rate 3. Influence
of charging on treatment
TB specialist ● ● ●
Wang
200718
2006 130 Yunnan Counties 10 mixed
income,
All free
Patient survey Non-adherence rate Village
doctors and
local CDC
staff
●
Wang
200921
2004-2007 607 unknown Counties 2 high
income,
All free
Patient survey Non-adherence rate Independent
investigator
●
NESS-TB
200217d
2000 1278 e Whole of
China
N-A N-A Patient survey 1. Non-adherence rate 2.
Influence of charging on
adherence
unknown ● ●
Hu
200819
2004 405 Chongqing Counties 4 mixed
income,
2 free 2
not free
1. Patient survey 2.
In-depth interview
1. Non-adherence rate 2.
Influence of charging on
adherence
Postgraduate
students
● ●
Xu
200920
2006 670 Jiangsu Counties 13 mixed
income,
All free
1. Patient survey 2.
In-depth interview
1. Non-adherence rate 2.
Influence of charging on
adherence
TB staff ● ●
Ai
201022
2006-2007 659 Shaanxi Counties 30 poor,
All free
Patient survey 1. Non-adherence rate 2.
Influence of charging on
adherence
Unknown ● ●
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Table 3 Description of included studies (Continued)
Sun
200723
2004-2005 473 Jiangsu County 1
unknown,
Free
Longitudinal: 3
interviews at 2nd,
5th treatment
month and
treatment
completion
1. Non-adherence rate 2.
Influence of charging on
adherence
TB staff ● ●
Xu
200424
unknown 30 Jiangsu Counties 2 middle
income,
1 free 1
not free
Focus Group
Discussions (FGDs)
Influence of charging on
adherence
Researcher
and
postgraduate
students
●
N-A: not applicable
a In the column “Questions”, point refer to which question the paper contributes data to
b Good follow up (>92% complete all interviews);
c After 10-12 months 11 people died and five could not be located.
d NESS-TB: National technical steering group of the epidemiological sampling survey for tuberculosis
e 900 new cases and 378 patients who received treatment
Table 4 Annual medical costs for one TB treatment (RMB). Excludes costs for diagnosis
Study Methods n Variables County or patient
group
TB
treatment
Annual
cost
% of annual
household
income
Liu
20108
Method: Survey Includes: All TB patients
Extent: 8 counties
163 Average expenditure in
previous month on TB
drugs and tests
Income below
poverty line
<3720/year (n =
24)
Free 1584 a 93%
Meng
200410
Method: Survey Includes: All patients Extent:
4 counties
312 Average total medical
annual cost per patient
Poor county 1 (n =
81)
Poor county 2 (n =
65)
Free
Free
3070
2241
119%
57%
Jackson
200611
Method: Case control Costs prospective
Includes: All patients Extent: 4 counties
160 Direct medical costs per
completed treatment
Mixed income (n =
144)
Free 1940 39% b
Zhang
200712
Method: Household survey Number:
143,991 people Includes: TB patients Extent:
National
180 Annual household medical
cost
Low income (n =
80)
Mixed 1241 42%
Xu
201013
Method: Survey Includes: All TB patients
Extent: 6 counties
501 Annual household medical
cost
Poor county 1 (n =
68)
Poor county 2 (n =
88)
Free
Free
5228
4079
65%
84%
Liu
200714
Method: Survey Includes: Random sample
(TB patients) Extent: 3 poor counties in
each of 4 provinces
889 Direct medical cost per
treatment
Province 1 (n =
217))
Province 2 (n =
228)
Province 3 (n =
223)
Province 4 (n =
221)
Free
Free
Free
Free
775
800
1760
445
8% c
11%
27%
5%
Xu
200615
Method: Cohort study Includes: All TB
patients Extent: 2 counties
465 Direct medical cost per
treatment
Middle county 1 (n
= 183)
Middle county 2 (n
= 282)
Free
Charged
90
704
2% d
12%
Zhan
20049e
Method: Survey Includes: All patientsf
Extent: 3 counties
257 Direct medical costs per
treatment
Middle county 1 (n
= 46)
Middle county 2 (n
= 105)
Free
Charged
1517
1754
NA
Huang
200916
Method: Survey Includes: Sample (TB
patients) Extent: 10 counties
100 Direct medical costs per
treatment
Unknown Free 1635 NA
NA: not available
a Monthly costs estimated multiplied by six; Monthly household income reported multiplied by twelve
b From reported average annual household income of the TB patients interviewed
c From total cost as a percentage of annual household expenditure
d Based on reported average annual household income of the TB patients interviewed
e Cost in US$ converted to RMB by exchange rate used in the study. One county excluded as data from health worker estimates
f Random sample in one of the three counties
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• RMB 445 to 1760 (US$ 54 to214) was the range
for the average medical cost per treatment in each
of 3 poor counties of 4 provinces in a sixth study,
representing 5% to 27% of annual household expen-
diture [14].
• RMB 90 to 1754 (US$10 to 213) was the direct
medical cost per treatment by county with or with-
out free treatment in two studies [9,15].
• RMB 1635 (US$ 199) was the average direct medi-
cal cost from diagnosis to treatment completion in
10 counties with free treatment in one study [16].
Relationships with cost: In 3 studies (Liu 2010, Meng
2004 and Zhang 2007) [8,10,12] charges were disaggre-
gated by household income, there was no obvious rela-
tionship between charges and the income category of
the household; and in Meng, between poor and middle
income counties (Table 5). However, the average cost as
a proportion of total household income increased in the
low income groups.
In two studies (Zhan 2004, Xu 2006) [9,15] comparing
counties, the “free treatment” counties had diagnostic
costs 2-3 times that the other counties that charge for
TB drugs, suggesting transfer of costs from one function
of the TB service to another. In one of the two studies
(Zhan 2004), drug treatment costs were high despite
this being a county with free treatment.
All but one study gave a single figure for “medical
costs”. The exception was Liu (2010) [8]: the authors
asked patients about the cost components, and showed
these consisted of prescribing of liver protection,
immune stimulant and anti-inflammatory drugs, and
monthly X-ray and blood tests, with an average of RMB
287 (US$ 40) charged to each patient in the previous
month. In the low income group, cost of liver protection
drugs was 71% of patient monthly income; 32% and 63%
of patient income being spent on ancillary drugs and
tests respectively.
Adherence to treatment
Ten studies were surveys in which the investigators
asked whether people who should have been on treat-
ment were actually taking their drugs (Table 6). The
large national sample survey in 2000 showed that 73%
of patients underwent interrupted or suspended treat-
ment (39% in TB services system and 79% in general
health system) [17].
In 6 smaller studies (Xu 2010, Wang 2007, Hu 2008,
Xu 2009, Wang 2009 and Ai 2010), failure to follow
standard treatment course varied from 3% to 25% across
these studies [13,18-22]. Although each study used dif-
ferent outcomes, all appeared to measure the point pre-
valence of non-adherence; this does not provide the
cumulative effect over the entire treatment period.
Three studies followed up a cohort (Jackson 2006, Xu
2006 and Sun 2007) reported rate of incomplete treat-
ment course from 5% to 13% [11,15,23].
Association between patient costs and adherence
The national survey and 4 smaller studies examined rea-
sons why patients had interrupted treatment (National
TB epidemiological survey 2002, Jackson 2006, Zhang
2007, Xu 2009 and Ai 2010). The percentage of non-
adherence for reasons of cost varied from 3% to 45% of
the total number of patients (Table 7) [11,12,17,20,22].
One study (Sun, 2007) examined the association
between treatment cost and adherence showing higher
cost with higher likelihood of non-adherence [23].
In the three studies that met our inclusion criteria for
qualitative designs, a link between costs and adherence
Table 5 Estimates of charging: medical cost for TB care by income category (RMB)
Study Cost variable County Income category a Average cost, % annual
household income
Low Middle High
Meng
200410
Total medical cost Middle 2099 2826 3105 75%
Middle 2104 1449 1680 27%
Poor 4015 2011 3238 119%
Poor 1843 2054 2894 57%
Zhang
200712
Annual household medical cost in household
with TB patient
Whole rural
China
1241
(42%)b
2061
(28%)b
2090
(19%)b
NA
Liu 20108 Monthly medical cost Mixed 264
(185%)c
280
(22%)c
332 (8%)c 18%c
NA: not available
a In Meng’s study, Income category was classified by per capita income per year (Low≤500; Middle 500-1000; High > 1000)
In Zhang’s study, each income category contained a third of the total number of households;
In Liu’s study, income category was classified by family monthly income (Low < 310; Middle 310-2600; High > 2600);
b Average annual household medical cost in household with TB patient as a percentage of annual household income in each income group;
c Average monthly medical cost as a percentage of family monthly income in each income group and at an average level.
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was identified in them all. Xu (2004), conducted in a
county that did not implement free treatment, reported
that treatment interruption occurred frequently due to
shortage of money, particularly after the first two
months of treatment [24]. Under free treatment, Xu
(2009) indicated that patients complained of adverse
reactions and low quality of free drugs; and doctors
admitted to recommending patients buy drugs rather
than taking the free drugs. Both patients and local doc-
tors reported that privately purchased drugs imposed a
higher financial burden to TB patients, sometimes
resulting in interrupted treatment [20]. In another study
(Hu 2008) the high cost of treatment was one of the
main reasons mentioned by patients who interrupted
treatment and village doctors agreed that financial bar-
riers led to default [19]. In two studies, patients specifi-
cally described having to pay extra for examinations and
additional drugs (mainly liver protection drugs) related
to treatment. Patients reported that these additional
costs were significant, accounted for a large part of
family income, and were related to treatment adherence
[19,20].
Discussion
Summary of findings
Overall, low income patients, defined at household or
district level, pay large amounts of money for medical
treatment of TB, ranging from US$ 149 to 724 (RMB
1241 to 5228); as a percentage of annual household
income, estimates range from 42% to 119%. One
national survey showed 73% of TB patients at survey
had interrupted or suspended treatment, and estimates
from 9 smaller more recent studies of showed that the
proportion of patients at the time of the survey who had
run out of drugs or were not taking them ranged from 3
to 25%. Synthesis of surveys and qualitative research
indicate that cost is the most cited reason for default.
Methodological and other potential limitations
Limitations of primary studies
Medical costs of TB treatment were measured in different
ways in each study. This includes two studies which used
annual household medical expenditure as proxy indicator.
Obtaining data on expenditure is complex. In these studies,
there is likely to be considerable variation in estimates due
Table 6 Non-adherence estimates from studies
Study Study design n Definition of non-adherence Non-adherence
rate
Xu 200615 Cohort: 4 interviews per
patient
465 Did not complete treatment course 5%-9%
Jackson 200611 Cohort: 2 interviews per
patient
144 Partial treatment 11%
Sun 200723 Cohort: 3 interviews per
patient
473 Interrupted or defaulted treatment 13%
Xu 201013 Patient survey 501 Defaulted and failed treatment 25%
Wang 200718 Patient survey 130 Stopped treatment > 2 weeks or missed over 20%
of pack
3% or 4%
Hu 200819 Patient survey 401 Missing last three doses, or no stock >1 week 13%
Xu 200920 Patient survey 670 Missing 10% or more of the total pack 12%
Wang 200921 Patient survey 537 Did not complete treatment course 15%
Ai 201022 Patient survey 659 Defaulted treatment a 12%
National TB epidemiological survey
200217
Patient survey 378 Interrupted or suspended treatment 73%
a 82 defaulted from treatment for which 20 died.
Table 7 Studies reporting relationship between charging and adherence
Study
design
Study Comment
Survey National TB epidemiological
survey 200217
45% (121/272) of patients having interrupted or suspended treatment due to financial difficulty
Zhang 200712 9% of households with TB suspects (2308) or patients defaulted due to financial burden
Xu 200920 16% (13/82) of non-adherence patients interrupted treatment because of high medical costs of the
treatment
Ai 201022 2% of patients who interrupted treatment (43) because of financial difficulty
Cohort Jackson 200611 3% (5/159) was too poor to begin treatment
Sun 200723 Patients who were charged high medical cost were more likely to interrupt treatment than patients
having lower medical costs
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to a) the rigor of the questions; b) the parameters of cost
estimated; and c) the region, province and locality where
the research was carried out, as costs vary considerably in
China. Few studies provided disaggregated data of the dif-
ferent components of the additional cost (such as tests,
additional drugs, or extending treatment).
Limitations of our review
This study reviews population-based studies other than
routine register data considering reliability of informa-
tion, but unpublished studies are not included due to
practical constraints. As well as the limitations in the
evidence we reviewed, we made assumptions in trying
to obtain a uniform measure of cost across studies,
which could contribute additional uncertainty to the
estimates. Another limitation of our study is that the
conclusions are based on indirect evidence and infer-
ence of an effect from very varied data from different
regions of China: we cannot be clear how far all these
findings are generalizable across the country.
Interpretation
In a primary health care system where fee for service is
normal, the Chinese government commendably made
TB drugs free. However, charges remain universal. It
appears free drugs are overlaid on an existing health sys-
tem based on fee for service, which proves problematic
given the existing organisational norms and culture. The
charges arise from additional and often unnecessary
drugs and tests beyond those supplied through the
national programme [8].Thus the revenue-driven prac-
tices in the general health system are influencing TB
control, including overprovision, poor referral (to keep
patients), and high hospitalisation costs [1,9].
We did identify policies to try and mitigate treatment
cost but data were limited. A number of pilot schemes
are underway, including decentralisation of TB diagnosis
and case management services to the township level
[25]; travel subsidies to get to clinic; payment to doctors
for directly observing treatment [26]; free treatment for
migrant patients [27]; and schemes linked to the New
Cooperative Medical Scheme (NCMS), including case
based payment.
The NCMS in China since 2003 has reached over 90%
of the rural population, and has improved the use of
healthcare by insured rural residents [28,29]. However,
reimbursement is low, and ambulatory patients with
chronic diseases have limited financial protection, and
still have to pay considerable amounts out of pocket
[30-32].
It seems inevitable that this will impact on completion
rates. Using surveys, there is a large variation in esti-
mates of TB completion. The national TB survey in
2000 reported a low adherence rate, particularly low in
the general health system. In recent studies reported
here, the results are the proportion of patients not tak-
ing drugs at the time of the survey: the cumulative fail-
ure to complete is likely to be higher. Hence, the
adherence on average was not so optimistic. What these
data do is generate a degree of uncertainty around true
completion rates.
TB treatment completion rate from the independent
studies reported in this review contrast with published
health service statistics which show very good perfor-
mance [33]. The Ministry of Health in China and
others have very clear targets for detection and treat-
ment, set by government and endorsed by World
Health Organization. It may be that the actual health
information systems do not operate as well as
expected, and where there are gaps in the data, health
workers worldwide tend to take the most optimistic
standpoint in their estimates. Thus the imputed com-
pletion rates may be overly optimistic. This we have
found in a study in Chongqing [19], although there has
been very little systematic assessment of the extent of
this problem.
Given the number of patients in China, poor or irre-
gular adherence could have massive public health impli-
cations, potentially increasing the risk of multi-drug
resistant TB and extremely drug-resistant TB develop-
ing. This will cause a worsening of the TB epidemic in
areas of China, and will increase the risk of morbidity
and mortality among the poor as well as the costs asso-
ciated with illness.
Conclusions
Despite a policy of free drug treatment for TB in China,
health services charge all income groups, and costs are
high. Adherence measured in cross sectional surveys is
often low, and the cumulative failure to adhere is likely
to be much higher. It is important that there is an open
debate between health providers, the Ministry of Health,
the World Health Organization and donors about these
realities, and discussion about the public health impact.
Policy makers need to consider appropriate steps to
document further problems with adherence, charging,
and how best to improve TB treatment delivery in poor
patients.
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